

ASX ANNNOUNCEMENT

24 JULY 2018

CardieX Reports Successful Initial Trial Results for Wearable Blood Pressure Sensor Technology

Highlights:

- CardieX has completed the 8-week trial with The Faculty of Medicine & Health Sciences at Macquarie University.
- Trial was part of the "Collaboration & Development Agreement" between Blumio, Inc, and CardieX to co-develop wearable blood pressure technology.
- Trial objective was to determine the degree of blood pressure data that could be extracted from Blumio's radar frequency sensor using CardieX Pulse Wave Analysis (PWA) technology and the comparison of that sensor data to Cardiex's (non-sensor based) XCEL device.
- Results showed that Blumio's sensor returns a high degree of cardiovascular blood pressure data as measured by CardieX technology.
- Trial also gave a strong indication that further central blood pressure (cBP) readings can be extracted from the sensor in a wearable device using CardieX neural learning and proprietary algorithms (A.I).
- The development of a commercial blood pressure and cBP wearable with PWA technology positions CardieX in a global \$1B+ market for wearable cardiovascular monitoring devices.
- Next phase 60-person Blumio sensor trial commences in late August, 2018 at Deborah Heart and Lung Center in New Jersey, USA.

CardieX Limited (ASX:CDX, the Company) is pleased to report encouraging results of a trial to validate the commercial application of the Company's pulse wave analysis (PWA) technology in a wearable blood pressure sensor.

The 8-week, 15-person trial with The Faculty of Medicine & Health Sciences at Macquarie University was part of a strategic collaboration with Blumio Inc, a Silicon Valley-based blood pressure sensor company.

As part of a multi-phase program, this first trial assessed the feasibility of obtaining cardiovascular blood pressure (BP) related data utilising Blumio's radar frequency sensor and analysing it via CardieX PWA technology. The trial was led by CardieX Principal Scientist, Dr. Ahmad Qasem together with Professor Alberto Avolio of Macquarie University.

The results of this initial trial demonstrated that using CardieX technology together with Blumio's sensor you could accurately extract cardiovascular signals from a variety of trial patient subjects with differing cardiovascular conditions as well as track changes in cardiovascular events in those patients – thereby making the sensor suitable for specific cardiovascular monitoring applications.

CardieX CEO, Craig Cooper commented:

"In order to develop a commercial wearable blood pressure sensor it requires the extraction of precise cardiovascular and blood pressure data from the relevant sensor. This initial trial is extremely encouraging as a clear demonstration of the use of our technology to extract specific blood pressure data from a wearable sensor.

We are continuing to refine the data obtained in the trial but our analysis to date has shown that with further neural learning - and the application of our proprietary algorithms - we have the ability to extract a wide range of commercially viable medical and consumer data from the sensor."

For more information please contact:

Chief Executive Officer
Craig Cooper
Ph: +61 429 993 399
c.cooper@atcormedical.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231

peter@nwrcommunications.com.au

About CardieX

CardieX is a Sydney based global health technology company focused on developing solutions for large-scale population health disorders. The Company's "AtCor Medical" division develops and markets products for the early detection of target organ damage and the management of cardiovascular and renal disease.

About Blumio

Blumio Inc, is a Silicon Valley based company that develops non-invasive radio frequency sensors designed to measure blood pressure and other cardiovascular diagnostics. Blumio is developing its sensor technology for integration with next generation wearable devices in order to provide better health diagnostic solutions.